Form 8-K - Current report:
SEC Accession No. 0001641172-25-001751
Filing Date
2025-03-31
Accepted
2025-03-31 16:20:36
Documents
22
Period of Report
2025-03-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 59677
2 ex4-1.htm EX-4.1 93381
3 ex4-2.htm EX-4.2 116248
4 ex4-3.htm EX-4.3 116958
5 ex5-1.htm EX-5.1 22564
6 ex10-1.htm EX-10.1 284317
7 ex99-1.htm EX-99.1 16258
8 ex5-1_001.jpg GRAPHIC 24185
9 image_001.jpg GRAPHIC 19502
10 image_005.jpg GRAPHIC 19502
  Complete submission text file 0001641172-25-001751.txt   1127530

Data Files

Seq Description Document Type Size
11 XBRL SCHEMA FILE ensc-20250331.xsd EX-101.SCH 3012
12 XBRL LABEL FILE ensc-20250331_lab.xml EX-101.LAB 34240
13 XBRL PRESENTATION FILE ensc-20250331_pre.xml EX-101.PRE 24163
24 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3701
Mailing Address 7946 IVANHOE AVENUE SUITE 201 LA JOLLA CA 92037
Business Address 7946 IVANHOE AVENUE SUITE 201 LA JOLLA CA 92037 (858) 263-4196
Ensysce Biosciences, Inc. (Filer) CIK: 0001716947 (see all company filings)

EIN.: 822755287 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38306 | Film No.: 25793573
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)